If a highly virulent pandemic strain were to emerge in today’s interconnected world, influenza has the potential to kill millions of people, especially in developing countries with limited to no resources for pandemic planning, preparedness, and outbreak response. PATH's work in developing thermostable influenza vaccines holds promise for extending product shelf life and easing logistics during introduction and rapid deployment to hard-to-reach populations—markedly improving developing-country preparedness and ability to contain the virus at its point of origin. This fact sheet describes our latest research achievements and next steps in product development.
Corporate author(s): PATH
Publication date: September 2013
110 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA